Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C17H17ClF6N2O
CAS Number:
Molecular Weight:
414.77
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
EC Number:
257-412-0
MDL number:
Product Name
Mefloquine hydrochloride, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white
solubility
DMSO: soluble 38 mg/mL, H2O: insoluble
SMILES string
Cl[H].[H][C@@]1(CCCCN1)[C@@H](O)c2cc(nc3c(cccc23)C(F)(F)F)C(F)(F)F
InChI
1S/C17H16F6N2O.ClH/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11;/h3-5,8,12,15,24,26H,1-2,6-7H2;1H/t12-,15+;/m1./s1
InChI key
WESWYMRNZNDGBX-YLCXCWDSSA-N
Application
Mefloquine hydrochloride has been used:
- to treat cochlear organotypic cultures with various doses to evaluate its role in cellular pathway involved in apoptosis
- in screening for in vitro antischistosomal activity
- in cytotoxicity assay of glioblastoma cells
Biochem/physiol Actions
Mefloquine is broadly used as an antimalarial drug. It inhibits 80S ribosomes of Plasmodium. It has numerous side effects like anxiety, dizziness, tremor, headache, and hearing loss. Mefloquine damages cochlear and vestibular hair cells through apoptosis. It also damages spiral ganglion neurons, degenerates cortical neuron and disrupts neuronal calcium homeostasis.
Blocker of gap junction channels Cx36 and Cx50.
Still not finding the right product?
Explore all of our products under Mefloquine hydrochloride
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mahadeo A Sukhai et al.
The Journal of clinical investigation, 123(1), 315-328 (2012-12-04)
Despite efforts to understand and treat acute myeloid leukemia (AML), there remains a need for more comprehensive therapies to prevent AML-associated relapses. To identify new therapeutic strategies for AML, we screened a library of on- and off-patent drugs and identified
Rithea Leang et al.
Antimicrobial agents and chemotherapy, 57(2), 818-826 (2012-12-05)
We describe here the results of antimalarial therapeutic efficacy studies conducted in Cambodia from 2008 to 2010. A total of 15 studies in four sentinel sites were conducted using dihydroartemisinin-piperaquine (DP) for the treatment of Plasmodium falciparum infection and chloroquine
Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis
Zhang SM and Coultas KA
International Journal for Parasitology, Drugs and Drug Resistance, 3(11), 28-34 (2013)
